Lucia Galán-Dávila

Lucia Galán-Dávila

Auto-generated profile, based on publicly available information

Lucia Galán-Dávila

D Hospital Clínico San Carlos , Madrid , Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2019 in Amyloid
Verified
Journal Article
Open access
ICIsabel Conceição
Isabel Conceição
TDThibaud Damy
Thibaud Damy
MRManuel Romero
Manuel Romero
LGLucía Galán
Lucía Galán
SAShahram Attarian
Shahram Attarian
MUMitsuharu Ueda
Mitsuharu Ueda
Diagnosis in the early stages of hereditary transthyretin (ATTR) amyloidosis is imperative to support timely treatment to prevent or delay disease progression. Genetic testing in the setting of genetic counselling enables identification of carriers of a TTR gene mutation who are therefore at risk of developing TTR-associated disease. Knowledge of different genotypes and how they manifest in symptomatic disease should facilitate development of a structured and targeted approach to enable diagnosis of symptomatic disease in ATTR amyloidosis mutation carriers on the first manifestation of the earliest detectable sign or symptom. A group of experts from across Europe, Israel and Japan met to reach a consensus on such an approach. The proposed approach involves establishing a baseline for key clinical parameters, determination of the timing and frequency of follow-up in TTR mutation carriers based on a predicted age of disease onset, and recognition of the likely initial clinical signs and symptoms aligned with the phenotype of the specific TTR gene mutation and family history. Minimum criteria for diagnosis of symptomatic disease have been agreed, which it is hoped will ensure diagnosis of ATTR amyloidosis at the earliest possible stage in people with a known TTR mutation.

22 July 2025 in Preprints.org
Verified
Preprint
Open access
LGLucia Galán-Dávila
Lucia Galán-Dávila
MRMónica A. López Rodríguez
Mónica A. López Rodríguez
TRTomás Ripoll-Vera
Tomás Ripoll-Vera
IMInmaculada Mediavilla
Inmaculada Mediavilla
JSJosé Francisco Soto
José Francisco Soto
MLManuel Leal
Manuel Leal
Background: Transthyretin amyloidosis (ATTR) is a multisystem, progressive, and potentially fatal condition. It is significantly under-recognized, leading to delayed diagnosis and treatment and poor outcomes. The CARABELA-ATTR initiative aims to address the challenges of ATTR management in the Spanish healthcare system. Methods: This initiative promotes collaboration between scientific societies, clinicians, and the pharmaceutical industry to optimize ATTR care using lean methodology. It included four phases: (1) characterization of ATTR clinical pathways; (2) validation and prioritization of areas for improvement and selection of quality indicators (QIs); (3) co-creation of solutions; and (4) dissemination of results. Results: A generic ATTR patient journey was defined, identifying four healthcare models with varying coordination and resources. Multidisciplinary discussions identified 13 areas for improvement, including deficient multidisciplinary coordination, lack of standardized diagnostic protocols, and uneven resource distribution. A set of QIs covering all aspects of care was defined. Validated solutions included establishing multidisciplinary teams, standardizing diagnostic and treatment protocols, and ensuring equitable access to advanced diagnostics and treatments. Conclusions: The CARABELA-ATTR initiative provides a framework that emphasizes multidisciplinary coordination, diagnostic and treatment protocols, continuous education for healthcare professionals and patients, and equitable access to resources, aiming to improve patient outcomes and quality of life.